We recently posted about the PTAB declining to sanction CFAD for filing IPRs. In light of that holding, Erich Spangenberg, owner of nXn Partners, revealed his intention to make publicly available substantially final draft versions of IPR petitions for pharmaceutical patents that he believes are invalid. Spangenberg does not care who…